+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 27 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
S

Actively Recruiting

Researchers are evaluating two treatment approaches for patients with acute atrial fibrillation or atrial flutter when rhythm control is desired. The study compares conventional acute cardioversion performed within 48 hours in the emergency department to elective delayed cardioversion performed approximately one week later in an out-patient clinic. The goal is to see if these arrhythmias can be safely managed with an elective timing approach. Participants are randomly assigned to either immediate cardioversion in the emergency department or to an elective delayed cardioversion after discharge. All patients receive anticoagulation treatment according to guidelines, with extra precautions such as transesophageal cardiac ultrasound if needed before delayed cardioversion. Patients in the elective group can choose early cardioversion if symptoms become unmanageable before the scheduled out-patient visit. Participants undergo follow-up visits including a cardiologist assessment about one week after enrollment and further assessments one month later with an ECG to check heart rhythm. Quality of life and symptom monitoring occur during the first week and one month after the clinic visit. Patients are then followed up for up to five years to monitor any medical interventions related to atrial fibrillation or flutter. New antiarrhythmic drugs like flecainide are not used during the first month.

All AgesAll GendersPhase Not Applicable
4 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are conducting a prospective observational cohort study in Finland to evaluate adolescent depression treatment pathways in primary care. The study focuses on adolescents aged 13 to 16 years attending grades 7 to 9 in selected schools, aiming to understand access to treatment and identify those who may benefit from adolescent interpersonal counseling IPC-A. The study compares IPC-A, a brief behavioral intervention, to treatment as usual and no treatment, assessing effectiveness and cost-effectiveness. The study involves adolescents completing surveys over six months about depressive symptoms, treatment motivation, and benefits or harms from treatment every two weeks. Caretakers will also provide information on adolescent support needs and treatment outcomes through surveys at six-month intervals. When applicable, professionals providing support will report on their training and treatment content. Register data on social welfare and health care service use will be collected from one year before to up to ten years after the study to inform cost and service provision. Participants will be followed for 12 months to measure outcomes including the proportion referred to specialized psychiatric services and changes in depression symptom scores. Data on received support and treatment response will be gathered from adolescents, caretakers, professionals, and patient records. The study will monitor benefits and harms of treatment, aiming to improve detection, equal access, and inform prevention strategies for adolescent depression.

Age: 13Years - 16YearsAll Genders
4 locations
C

Actively Recruiting

This research focuses on men suspected of having prostate cancer and aims to compare two approaches for deciding when to perform prostate biopsies after MRI scans. The study evaluates whether biopsies guided by shared decision-making based on prostate cancer risk estimation differ in detecting significant cancer compared to biopsies performed routinely after MRI. Researchers seek to improve diagnosis while reducing unnecessary biopsies and have enrolled 600 patients from multiple hospital districts for this randomized trial. Participants undergo biparametric MRI bpMRI scans interpreted by an experienced urologist using specific scoring systems. Men are randomly assigned to two groups in the control group, all men receive biopsies after MRI in the intervention group, biopsies are done only after a shared decision process considering individual risk. Biopsies involve systematic and targeted samples depending on MRI findings. Men without biopsies or with negative results enter a five-year follow-up with regular PSA tests. During the study, participants undergo MRI scans, prostate biopsies when indicated, and follow-up PSA testing every six months for five years. Researchers assess the proportion of men with clinically significant prostate cancer Gleason 43 or higher at baseline, biopsy complications, anxiety levels through questionnaires, and biopsy rates. Long-term follow-up continues for 15 years using health records and registries to monitor outcomes beyond the initial study period.

Age: 18Years +MALEPhase Not Applicable
4 locations
C

Actively Recruiting

Researchers are comparing the safety and effectiveness of laparoscopic cholecystectomy versus a wait-and-see approach in elderly patients who have had successful endoscopic removal of common bile duct stones. The study aims to determine if waiting without immediate surgery is not worse than having the gallbladder removed laparoscopically. The main goal is to observe death, major postoperative complications, or recurrent biliary disease within one year after randomization. Four hundred participants aged 75 or older with cleared bile duct stones are randomly assigned to one of two groups. One group receives laparoscopic cholecystectomy within two weeks after stone removal, while the other group is managed without surgery initially but can have cholecystectomy later if needed. An interim safety analysis is planned after 100 participants to ensure no significant differences arise between groups. The trial may end early if strong evidence shows a difference in outcomes. Participants are followed for up to one year after randomization to track the composite outcome of death, major complications, or biliary events. Researchers also monitor quality of life, survival, healthcare costs, and pain related to biliary issues at various time points. The study includes assessments at 30, 180, and 365 days, with additional monitoring of hospitalizations and complications extending to two years in some measures.

Age: 75Years +All GendersPhase Not Applicable
12 locations
S

Actively Recruiting

Researchers are investigating whether adding azithromycin before hysterectomy surgery can reduce infections compared to using cefuroxime alone. The study focuses on women undergoing hysterectomy for benign reasons, aiming to lower the risk of deep infections that can occur within 30 days after surgery. It also explores other infections like superficial infections, urinary tract infections, and postoperative fever, as well as the role of bacterial vaginosis and microbiome in these infections. Participants receive either azithromycin tablets plus cefuroxime or a placebo plus cefuroxime before surgery. Azithromycin is given orally on the day of surgery upon hospital arrival, while cefuroxime dose varies based on body mass index and is administered intravenously before the surgical incision. The trial compares infection rates between these two groups during the first 30 days after hysterectomy. During the study, participants are monitored for deep infections, other infections, and fever episodes occurring within 30 days post-surgery. Researchers assess side effects of the antibiotics and collect data related to the presence of bacterial vaginosis and microbiome changes. The study is randomized and triple masked, with follow-up occurring during the first month after surgery to evaluate infection outcomes and safety.

Age: 18Years +FEMALEPhase Not Applicable
6 locations
C

Actively Recruiting

This research evaluates the use of drug-coated balloons DCB compared to drug-eluting stents DES in patients with stable coronary artery disease CAD or acute coronary syndrome ACS who are at high risk of bleeding. The study aims to test whether using DCB with a shorter dual antiplatelet therapy DAPT regimen is not worse than using DES with a longer DAPT duration. If the DCB strategy is found not inferior, its superiority over DES will be further assessed. Participants will receive either a DCB or a DES during percutaneous coronary intervention PCI. The DCB group uses the SeQuent Please device combined with a tailored antithrombotic regimen based on patient stability and oral anticoagulation use. The DES group involves implantation of various CE-marked drug-eluting stents alongside individualized antithrombotic treatment. Treatment regimens vary between stable patients and those with ACS, with differences in DAPT duration and lifelong therapies. Throughout the study, participants are monitored for major adverse cardiac events MACE and bleeding episodes using the BARC classification over 12 months as the primary outcome. Additional outcomes include mortality, revascularization events, myocardial infarction, stroke, and bleeding tracked up to 36 months. The study uses a randomized, triple-blind design to compare these treatments with ongoing safety and efficacy assessments.

Age: 18Years +All GendersPhase Not Applicable
14 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
E

Actively Recruiting

Carpal tunnel syndrome is a common nerve compression disorder in the upper limbs causing pain, numbness, and tingling in the fingers, often worse at night. The FINCROSS trial is a randomized crossover study that evaluates the effects of night-time and full-time wrist splinting compared to no treatment. It also aims to identify which patients might benefit most from splinting and whether a positive response reduces the need for surgery. Participants will undergo three treatment periods in random order wearing a wrist splint at night for six weeks, wearing the splint day and night for six weeks, and a six-week period without treatment. Each treatment phase is separated by a three-week washout period, making the full sequence 24 weeks long. Participants will also perform self-administered wrist stretching exercises throughout the study and avoid other medical interventions. During the study, participants will be assessed using symptom scales such as the 6-item CTS Symptoms Scale and the Boston Carpal Tunnel Questionnaire at baseline, mid-treatment, end of each treatment, and one year after randomization. Researchers will monitor symptom changes, quality of life, adverse effects, need for surgery, and use of escape treatments. Follow-up continues up to one year after starting the study.

Age: 18Years +All GendersPhase Not Applicable
6 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of trapeziectomy surgery compared to sham surgery in adults with persistent and painful osteoarthritis at the base of the thumb. This multi-center, randomized, placebo-controlled trial aims to measure patient-reported pain and hand function using the Patient Rated Wrist and Hand Evaluation PRWHE six months after treatment. The study also monitors secondary outcomes such as grip strength and overall improvement over a period extending up to five years. Participants are randomly assigned to receive either the trapeziectomy procedure, which involves surgically removing the trapezium bone, or a sham surgery consisting of only a skin incision. There is also a non-randomized observational group receiving trapeziectomy without blinding. The trial includes follow-up assessments at multiple time points including 3 months, 1 year, 2 years, and 5 years after randomization, with additional monitoring after any secondary trapeziectomy if needed. Throughout the study, participants will undergo evaluations of wrist and hand function, pain levels, grip and pinch strength, medication use, and quality of life through questionnaires and physical tests. Safety is closely monitored during surgery and postoperatively. The total duration of participation includes long-term follow-up assessments lasting up to five years to understand lasting effects and changes in symptoms.

Age: 45Years +All GendersPhase Not Applicable
4 locations

1-10 of 27

1